Bio-Rad Laboratories Quarterly Income Statement
NYSE: BIO.BHealthcareMedical DevicesUSD
At close: Aug 20, 10:24 AM ET · Delayed 15 min
Bio-Rad Laboratories revenue and earnings
In the quarter ended Jun 30, 2026, Bio-Rad Laboratories generated $651.0 million in revenue, down 0.1% from the same quarter a year earlier. Net income was $371.4 million (+16.9% year over year), for a net margin of 57.1% versus a median of 10.9% in the prior 5 quarters. Gross margin was 53.1% (up from 53.0%) and operating margin 11.2%.
Diluted earnings per share came in at $13.85, up from $11.67.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Rad Laboratories income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 651.00M | 592.10M | 693.20M | 653.00M | 651.60M | 585.40M | 667.50M | 649.70M | 638.50M | 610.80M | 681.12M | 632.12M |
| Revenue growth (YoY) | -0.09% | +1.14% | +3.85% | +0.51% | +2.05% | -4.16% | -2.00% | +2.78% | -6.26% | -9.76% | -6.73% | -7.15% |
| Cost of Revenue | 305.20M | 282.70M | 348.00M | 309.60M | 306.30M | 279.40M | 325.60M | 293.80M | 283.40M | 284.90M | 314.81M | 296.44M |
| Gross Profit | 345.80M | 309.40M | 345.20M | 343.40M | 345.30M | 306.00M | 342.00M | 355.90M | 355.10M | 325.90M | 366.30M | 335.70M |
| Operating Expenses | 273.20M | 275.30M | 464.10M | 278.10M | 268.20M | 282.30M | 283.70M | 291.40M | 253.60M | 281.30M | 270.98M | 244.75M |
| Research & Development | 61.20M | 62.90M | 70.30M | 71.30M | 60.50M | 73.50M | 79.60M | 91.00M | 58.90M | 66.40M | 63.87M | 43.53M |
| Selling, General & Admin | 212.00M | 212.40M | 221.00M | 206.80M | 207.70M | 208.80M | 204.00M | 200.40M | 194.70M | 214.90M | 207.12M | 201.20M |
| Operating Income | 72.60M | 34.10M | -118.90M | 65.30M | 77.10M | 23.70M | 58.30M | 64.50M | 101.50M | 44.60M | 95.32M | 90.95M |
| Interest Expense | 12.10M | 12.30M | 12.10M | 12.30M | 12.60M | 12.00M | 12.20M | 12.10M | 12.30M | 12.30M | 12.32M | 12.40M |
| Other Income (Expense) | 23.40M | 24.20M | 28.60M | 8.30M | 16.20M | 37.20M | 19.60M | 17.90M | 18.20M | 34.60M | 19.14M | 20.45M |
| Pretax Income | 542.10M | -689.80M | 929.20M | -431.10M | 414.00M | 83.40M | -908.90M | 861.60M | -2.79B | 491.10M | 428.40M | 137.10M |
| Income Tax | 170.70M | -162.70M | 209.20M | -89.20M | 96.20M | 19.40M | -193.10M | 208.40M | -620.80M | 107.20M | 78.66M | 30.84M |
| Net Income | 371.40M | -527.10M | 720.00M | -341.90M | 317.80M | 64.00M | -715.80M | 653.20M | -2.17B | 383.90M | 349.70M | 106.30M |
| Net Income growth (YoY) | +16.87% | -923.59% | — | -152.34% | — | -83.33% | -304.69% | +514.49% | — | +456.38% | -57.75% | — |
| EPS (Basic) | 13.89 | -19.55 | 26.61 | -12.70 | 11.67 | 2.29 | -25.57 | 23.37 | -76.26 | 13.46 | 12.15 | 3.65 |
| EPS (Diluted) | 13.85 | -19.55 | 26.59 | -12.70 | 11.67 | 2.29 | -25.57 | 23.34 | -76.26 | 13.45 | 12.14 | 3.64 |
| Shares Outstanding (Basic) | 26.75M | 26.96M | — | 26.92M | 27.23M | 27.94M | — | 27.95M | 28.39M | 28.52M | — | 29.10M |
| Shares Outstanding (Diluted) | 26.81M | 26.96M | — | 26.92M | 27.23M | 27.95M | — | 27.98M | 28.39M | 28.54M | — | 29.22M |
| Gross Margin | 53.12% | 52.25% | 49.80% | 52.59% | 52.99% | 52.27% | 51.24% | 54.78% | 55.61% | 53.36% | 53.78% | 53.11% |
| Operating Margin | 11.15% | 5.76% | -17.15% | 10.00% | 11.83% | 4.05% | 8.73% | 9.93% | 15.90% | 7.30% | 13.99% | 14.39% |
| Net Margin | 57.05% | -89.02% | 103.87% | -52.36% | 48.77% | 10.93% | -107.24% | 100.54% | -339.15% | 62.85% | 51.34% | 16.82% |
This table shows 12 quarterly periods of Bio-Rad Laboratories's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BIO.B's reporting calendar. What is a income statement?